Nucleix’s Bladder EpiCheck® Receives FDA 510(k) Clearance for Monitoring of Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Bladder EpiCheck^® for use as a non-invasive method for surveillance of tumor recurrence in patients previously diagnosed with non-muscle invasive bladder cancer (NMIBC), in conjunction with cystoscopy.